HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes.

Abstract
Mucosally induced immunological tolerance is an attractive strategy for preventing or treating illnesses resulting from untoward inflammatory immune reactions against self- or non-self-antigens. Oral administration of relevant autoantigens and allergens has been reported to delay or suppress onset of clinical disease in a number of experimental autoimmune and allergic disorders. However, the approach often requires repeated feeding of large amounts of tolerogens over long periods and is only partly effective in animals already systemically sensitized to the ingested antigen such as in animals already harboring autoreactive T cells, and thus presumably also in humans with an autoimmune disease. We have recently shown that oral administration of microgram amounts of antigen coupled to cholera toxin B subunit (CTB), can effectively suppress systemic T cell reactivity in naive as well as in immune animals. We now report that feeding small amounts (2-20 microg) of human insulin conjugated to CTB can effectively suppress beta cell destruction and clinical diabetes in adult nonobese diabetic (NOD) mice. The protective effect could be transferred by T cells from CTB-insulin-treated animals and was associated with reduced lesions of insulitis. Furthermore, adoptive co-transfer experiments involving injection of Thy-1,2 recipients with diabetogenic T cells from syngeneic mice and T cells from congenic Thy-1,1 mice fed with CTB-insulin demonstrated a selective recruitment of Thy-1,1 donor cells in the peripancreatic lymph nodes concomitant with reduced islet cell infiltration. These results suggest that protection against autoimmune diabetes can be achieved by feeding minute amounts of a pancreas islet cell autoantigen linked to CTB and appears to involve the selective migration and retention of protective T cells into lymphoid tissues draining the site of organ injury.
AuthorsI Bergerot, C Ploix, J Petersen, V Moulin, C Rask, N Fabien, M Lindblad, A Mayer, C Czerkinsky, J Holmgren, C Thivolet
JournalProceedings of the National Academy of Sciences of the United States of America (Proc Natl Acad Sci U S A) Vol. 94 Issue 9 Pg. 4610-4 (Apr 29 1997) ISSN: 0027-8424 [Print] United States
PMID9114038 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Immunoconjugates
  • Insulin
  • Toxoids
  • cholera toxoid
  • Cholera Toxin
Topics
  • Administration, Oral
  • Adoptive Transfer
  • Animals
  • Cell Movement
  • Cholera Toxin
  • Diabetes Mellitus, Type 1 (prevention & control)
  • Female
  • Immunoconjugates (therapeutic use)
  • Immunosuppression Therapy
  • Insulin (therapeutic use)
  • Islets of Langerhans (immunology)
  • Lymph Nodes (immunology)
  • Mice
  • Mice, Inbred NOD
  • T-Lymphocytes (immunology, transplantation)
  • Toxoids (therapeutic use)
  • Vibrio cholerae

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: